Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,494.00    24.00 (0.97%)
Bid:
2,484.00
Ask:
2,488.00
Spread: 4.00 (0.161%)
Market Cap: £8.01b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

20 Apr 2022 07:00

RNS Number : 6454I
Bunzl PLC
20 April 2022
 

20 April 2022

 

BUNZL Q1 TRADING STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 31 December 2021.

 

Bunzl's diversified and resilient business model has delivered strong growth, with Group revenue in the first quarter up 13.2% at actual exchange rates and 12.5% at constant exchange rates. At constant exchange rates, underlying revenue growth which is organic growth adjusted for trading days was 11.0%, mainly driven by inflation, with fewer trading days than the comparable period negatively impacting revenue by 1.7%. Acquisitions contributed further growth of 3.2% at constant exchange rates.

 

Underlying revenue growth of 11.0% was driven by continued momentum in the base business which contributed 17% growth, which significantly benefited from inflation. This was partially offset by the expected decline in sales from the top 8 Covid-19 related products which impacted underlying revenue by 6%, driven by product deflation compared to the prior year period. Overall, inflation remained particularly supportive to our businesses in North America, while the UK & Ireland and Continental Europe delivered very strong growth compared to the prior year due to inflation and recovery of the base business.

 

The Group's guidance remains unchanged. At constant exchange rates the Group expects moderate revenue growth in 2022, driven by the impact of acquisitions completed in the last 12 months and supported by a slight increase in organic revenue. Continued recovery of the base business is expected to be partially offset by the further normalisation of sales of Covid-19 related products. We also expect Group operating margin in 2022 to be slightly higher than historical levels.

 

Commenting on today's results, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Our entrepreneurial teams have continued to deliver good growth through a combination of passing on substantial inflation and volume growth, supported by recovering markets and with our performance over the last two years further strengthening our competitive position. Our diversified portfolio remains a key determinant of the strength and resilience of our performance. We continue to focus on delivering our long-term strategic objectives that will drive further compounding growth. Our acquisition pipeline is active and supported by our strong balance sheet."

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations

Tel: +44 (0)20 7725 5000

Tulchan

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUGDSBXBDGDC
Date   Source Headline
3rd Jan 202311:43 amRNSTotal Voting Rights
21st Dec 20227:00 amRNSTrading Statement
20th Dec 20227:00 amRNSAcquisition
14th Dec 20228:00 amRNSAdditional Listing
8th Dec 202212:56 pmRNSHolding(s) in Company
5th Dec 20229:45 amRNSDirector/PDMR Shareholding
1st Dec 20222:34 pmRNSTotal Voting Rights
29th Nov 20223:21 pmRNSDirector/PDMR Shareholding
11th Nov 20229:00 amRNSPublication of Admission Particulars
4th Nov 202212:08 pmRNSDirector/PDMR Shareholding
2nd Nov 20224:20 pmRNSDirector/PDMR Shareholding
1st Nov 20223:00 pmRNSTotal Voting Rights
1st Nov 202210:00 amRNSBlock listing Interim Review
20th Oct 20227:00 amRNSTrading Statement
11th Oct 20227:00 amRNSInvestor event
7th Oct 20224:11 pmRNSDirector/PDMR Shareholding
4th Oct 20224:54 pmRNSDirector/PDMR Shareholding
3rd Oct 20223:13 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSHolding(s) in Company
7th Sep 202210:59 amRNSDirector/PDMR Shareholding
1st Sep 202211:08 amRNSTotal Voting Rights
31st Aug 20221:46 pmRNSDirector/PDMR Shareholding
30th Aug 202210:00 amRNSDividend Declaration
30th Aug 20227:00 amRNSHalf-year Report
4th Aug 20229:19 amRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSAcquisition
1st Aug 20223:07 pmRNSTotal Voting Rights
1st Aug 202210:00 amRNSDirector Declaration
29th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
19th Jul 20227:00 amRNSDirectorate Change
12th Jul 202210:32 amRNSDirector/PDMR Shareholding
6th Jul 20225:12 pmRNSDirector/PDMR Shareholding
1st Jul 20222:18 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSTrading Statement
14th Jun 20227:00 amRNSAcquisition
8th Jun 202212:44 pmRNSDirector/PDMR Shareholding
1st Jun 202210:42 amRNSTotal Voting Rights
11th May 20228:00 amRNSAdditional Listing
5th May 202211:00 amRNSDirector/PDMR Shareholding
3rd May 202211:00 amRNSTotal Voting Rights
3rd May 202210:00 amRNSBlock listing Interim Review
28th Apr 20228:00 amRNSAdditional Listing
20th Apr 20225:17 pmRNSResult of AGM
20th Apr 20227:00 amRNSTrading Statement
19th Apr 20224:59 pmRNSDirector/PDMR Shareholding
8th Apr 20225:37 pmRNSDirector/PDMR Shareholding
8th Apr 20225:36 pmRNSDirector/PDMR Shareholding
7th Apr 20222:45 pmRNSDirector/PDMR Shareholding
5th Apr 20224:03 pmRNSDirector/PDMR Shareholding
1st Apr 20223:52 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.